← ANALYST RATINGS · TIPRANKS
Kyverna Therapeutics, Inc. (KYTX): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $29.00, the highest $33.00, the lowest $25.00. The average is +411.5% from the last price of $5.67.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $6.00 → $5.50−8.3% | Hold | −3.0% | Reiterated | 16.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $6.00 → $5.50−8.3% | Hold | −3.0% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $6.00 → $5.50−8.3% | Hold | −3.0% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $6.00 → $5.50−8.3% | Hold | −3.0% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $6.00 → $5.50−8.3% | Hold | −3.0% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $6.00 → $5.50−8.3% | Hold | −3.0% | Reiterated | 14.10.26on TipRanks 18:05 | — | |
| Mitchell Kapoor★★★★★★★★★★#1086 · hits 45% · avg +12.2% | H.C. Wainwright | $25.00 | Buy | +340.9% | Reiterated | 25.09.26on TipRanks 07:07 | −3.1%next day +0.9% · 5 days −8.4% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $33.00 | Buy | +482.0% | Reiterated | 25.09.26on TipRanks 05:30 | −3.1%next day +0.9% · 5 days −8.4% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Buy | — | Reiterated | 24.09.26on TipRanks 08:45 | −1.0%next day −3.1% · 5 days −6.3% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $33.00 | Buy | +482.0% | Assigned | 12.08.26on TipRanks 08:20 | +0.1%next day −0.3% · 5 days +10.6% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $30.00 → $29.00−3.3% | Buy | +411.5% | Assigned | 13.05.26on TipRanks 06:45 | +4.8%next day −1.2% · 5 days −20.4% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $25.00 → $32.00+28.0% | Buy | +464.4% | Reiterated | 15.12.25on TipRanks 15:15 | +23.4%next day −5.1% · 5 days −25.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Kyverna Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $30.33 at a price of $6.80 (+346.1%); now: $30.33 at $5.67 (+435.0%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 5 | 3 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.69 (from $-0.77 to $-0.65). Last quarter: $-0.63.
Best top-analyst consensus in the sector · Healthcare
About Kyverna Therapeutics, Inc.
- CEO: Warner Biddle
- Employees: 149
- 5980 Horton Street, Emeryville, CA, 94608, US
- kyvernatx.com
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Data from the stock’s TipRanks forecast page, read 204 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗